SAFETY DATA SHEET

Agilent Technologies

Anti-FITC-AP CISH Accessory Kit (Dako Omnis), Box A

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Product name : Anti-FITC-AP CISH Accessory Kit (Dako Omnis), Box A

Part no. (chemical kit) : K589911-21

Part no. :

CISH Endogenous Enzyme Block (Dako Omnis)	K589911-21510
Anti-FITC-AP (Dako Omnis)	K589911-21511
BCIP-NBT Substrate (Dako Omnis)	K589911-21512

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory use

CISH Endogenous Enzyme Block (Dako Omnis)	13.7 ml
Anti-FITC-AP (Dako Omnis)	9.3 ml
BCIP-NBT Substrate (Dako Omnis)	26.9 ml

None known.

1.3 Details of the supplier of the safety data sheet

Agilent Technologies Deutschland GmbH
Hewlett-Packard-Str. 8
76337 Waldbronn
Germany
0800 603 1000

e-mail address of person responsible for this SDS : pdl-msds_author@agilent.com

1.4 Emergency telephone number

Emergency telephone number (with hours of operation) : CHEMTREC®: +353 1 901 4670

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition :

CISH Endogenous Enzyme Block (Dako Omnis)	Mixture
Anti-FITC-AP (Dako Omnis)	Mixture
BCIP-NBT Substrate (Dako Omnis)	Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

BCIP-NBT Substrate (Dako Omnis)

H360D	REPRODUCTIVE TOXICITY	Category 1B
H412	LONG-TERM (CHRONIC) AQUATIC HAZARD	Category 3

CISH Endogenous Enzyme Block (Dako Omnis)	The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.
Anti-FITC-AP (Dako Omnis)	The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.
BCIP-NBT Substrate (Dako Omnis)	The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

SECTION 2: Hazards identification

Ingredients of unknown toxicity	:	Anti-FITC-AP (Dako Omnis)	Percentage of the mixture consisting of ingredient(s) of unknown acute dermal toxicity: 1 - 10% Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1 - 10% Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: 1 - 10%
		BCIP-NBT Substrate (Dako Omnis)	Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1 - 10%
Ingredients of unknown ecotoxicity	:	Anti-FITC-AP (Dako Omnis)	Contains 3% of components with unknown hazards to the aquatic environment

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms : BCIP-NBT Substrate (Dako Omnis)

Signal word	:	CISH Endogenous Enzyme Block (Dako Omnis)	No signal word.
		Anti-FITC-AP (Dako Omnis)	No signal word.
		BCIP-NBT Substrate (Dako Omnis)	Danger
Hazard statements	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	H360D - May damage the unborn child. H412 - Harmful to aquatic life with long lasting effects.

Precautionary statements

Prevention	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	P201 - Obtain special instructions before use. P280 - Wear protective gloves, protective clothing and eye or face protection. P273 - Avoid release to the environment.
Response	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	P308 + P313 - IF exposed or concerned: Get medical advice or attention.
Storage	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	Not applicable.

SECTION 2: Hazards identification

Disposal	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	:	BCIP-NBT Substrate (Dako Omnis)	N, N-dimethylformamide
Supplemental label elements	:	CISH Endogenous Enzyme Block (Dako Omnis)	Safety data sheet available on request.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	Not applicable.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	Restricted to professional users.

Special packaging requirements

Tactile warning of danger	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	CISH Endogenous Enzyme Block (Dako Omnis)	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
		Anti-FITC-AP (Dako Omnis)	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
		BCIP-NBT Substrate (Dako Omnis)	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	CISH Endogenous Enzyme Block (Dako Omnis)	None known.
		Anti-FITC-AP (Dako Omnis)	Contains one or more substances considered to have endocrine-disrupting properties.
		BCIP-NBT Substrate (Dako Omnis)	None known.

Substances identified as having endocrine disruptor properties :

Ingredient name	Impact
Anti-FITC-AP (Dako Omnis)	
Polyoxyethylene octyl phenyl ether	Environment

SECTION 3: Composition/information on ingredients

3.1 Substances : CISH Endogenous Enzyme Block (Dako Omnis) — Mixture
Anti-FITC-AP (Dako Omnis) — Mixture
BCIP-NBT Substrate (Dako Omnis) — Mixture

Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Type
CISH Endogenous Enzyme Block (Dako Omnis)					
hydrogen peroxide solution	EC: 231-765-0 CAS: 7722-84-1 Index: 008-003-00-9	<5	Ox. Liq. 1, H271 Acute Tox. 4, H302 Acute Tox. 4, H332 Skin Corr. 1A, H314 Eye Dam. 1, H318 STOT SE 3, H335	Ox. Liq. 1, H271: C ≥ 70% Ox. Liq. 2, H272: 50% ≤ C < 70% ATE [Oral] = 693.7 mg/kg ATE [Inhalation (vapours)] = 11 mg/l Skin Corr. 1A, H314: C ≥ 70% Skin Corr. 1B, H314: 50% ≤ C < 70% Skin Irrit. 2, H315: 35% ≤ C < 50% Eye Dam. 1, H318: C ≥ 8% Eye Irrit. 2, H319: 5% ≤ C < 8% STOT SE 3, H335: C ≥ 35%	[1] [2]
Anti-FITC-AP (Dako Omnis)					
Polyoxyethylene octyl phenyl ether	CAS: 9002-93-1	≤0.12	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 Aquatic Acute 1, H400 Aquatic Chronic 1, H410	ATE [Oral] = 1800 mg/kg M [Acute] = 10 M [Chronic] = 1	[1] [2]
BCIP-NBT Substrate (Dako Omnis)					
N, N-dimethylformamide	EC: 200-679-5 CAS: 68-12-2 Index: 616-001-00-X	≤3	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Eye Irrit. 2, H319 Repr. 1B, H360D	ATE [Dermal] = 1500 mg/kg ATE [Inhalation (vapours)] = 11 mg/l	[1] [2]
magnesium chloride	EC: 232-094-6 CAS: 7786-30-3	≤1	Aquatic Chronic 1, H410 **See Section 16 for the full text of the H statements declared above.**	M [Chronic] = 1	[1]

SECTION 3: Composition/information on ingredients

There are no additional ingredients present which, within the current knowledge of the supplier, are classified and contribute to the classification of the substance and hence require reporting in this section.

Type	
CISH Endogenous Enzyme Block (Dako Omnis)	[1] Substance classified with a health or environmental hazard [2] Substance with a workplace exposure limit
Anti-FITC-AP (Dako Omnis)	[1] Substance classified with a health or environmental hazard [2] Substance of equivalent concern
BCIP-NBT Substrate (Dako Omnis)	[1] Substance classified with a health or environmental hazard [2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	:	CISH Endogenous Enzyme Block (Dako Omnis)	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
		Anti-FITC-AP (Dako Omnis)	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
		BCIP-NBT Substrate (Dako Omnis)	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
Inhalation	:	CISH Endogenous Enzyme Block (Dako Omnis)	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
		Anti-FITC-AP (Dako Omnis)	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
		BCIP-NBT Substrate (Dako Omnis)	Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Skin contact	:	CISH Endogenous Enzyme Block (Dako Omnis)	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
		Anti-FITC-AP (Dako Omnis)	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
		BCIP-NBT Substrate (Dako Omnis)	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.

SECTION 4: First aid measures

Ingestion	:	CISH Endogenous Enzyme Block (Dako Omnis)	Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
		Anti-FITC-AP (Dako Omnis)	Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
		BCIP-NBT Substrate (Dako Omnis)	Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	:	CISH Endogenous Enzyme Block (Dako Omnis)	No action shall be taken involving any personal risk or without suitable training.
		Anti-FITC-AP (Dako Omnis)	No action shall be taken involving any personal risk or without suitable training.
		BCIP-NBT Substrate (Dako Omnis)	No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects

Eye contact	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.
Inhalation	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.
Skin contact	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.

SECTION 4: First aid measures

Ingestion	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	No specific data.
Inhalation	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations
Skin contact	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations
Ingestion	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	:	CISH Endogenous Enzyme Block (Dako Omnis)	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
		Anti-FITC-AP (Dako Omnis)	In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
		BCIP-NBT Substrate (Dako Omnis)	In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

SECTION 4: First aid measures

Specific treatments	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific treatment.
		Anti-FITC-AP (Dako Omnis)	No specific treatment.
		BCIP-NBT Substrate (Dako Omnis)	No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	:	CISH Endogenous Enzyme Block (Dako Omnis)	Use an extinguishing agent suitable for the surrounding fire.
		Anti-FITC-AP (Dako Omnis)	Use an extinguishing agent suitable for the surrounding fire.
		BCIP-NBT Substrate (Dako Omnis)	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	:	CISH Endogenous Enzyme Block (Dako Omnis)	None known.
		Anti-FITC-AP (Dako Omnis)	None known.
		BCIP-NBT Substrate (Dako Omnis)	None known.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture	:	CISH Endogenous Enzyme Block (Dako Omnis)	In a fire or if heated, a pressure increase will occur and the container may burst.
		Anti-FITC-AP (Dako Omnis)	In a fire or if heated, a pressure increase will occur and the container may burst.
		BCIP-NBT Substrate (Dako Omnis)	In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.
Hazardous combustion products	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides sulfur oxides phosphorus oxides
		BCIP-NBT Substrate (Dako Omnis)	Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides halogenated compounds

5.3 Advice for firefighters

SECTION 5: Firefighting measures

Special precautions for fire-fighters	:	CISH Endogenous Enzyme Block (Dako Omnis)	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
		Anti-FITC-AP (Dako Omnis)	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
		BCIP-NBT Substrate (Dako Omnis)	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	:	CISH Endogenous Enzyme Block (Dako Omnis)	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.
		Anti-FITC-AP (Dako Omnis)	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.
		BCIP-NBT Substrate (Dako Omnis)	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	:	CISH Endogenous Enzyme Block (Dako Omnis)	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
		Anti-FITC-AP (Dako Omnis)	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
		BCIP-NBT Substrate (Dako Omnis)	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	CISH Endogenous Enzyme Block (Dako Omnis)	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
		Anti-FITC-AP (Dako Omnis)	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
		BCIP-NBT Substrate (Dako Omnis)	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

SECTION 6: Accidental release measures

6.2 Environmental precautions

CISH Endogenous Enzyme Block (Dako Omnis)	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
Anti-FITC-AP (Dako Omnis)	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
BCIP-NBT Substrate (Dako Omnis)	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up

CISH Endogenous Enzyme Block (Dako Omnis)	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Anti-FITC-AP (Dako Omnis)	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. May be harmful to the environment if released. Dispose of spillages under controlled conditions.
BCIP-NBT Substrate (Dako Omnis)	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

6.4 Reference to other sections

: See Section 1 for emergency contact information.
See Section 8 for information on appropriate personal protective equipment.
See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Protective measures

CISH Endogenous Enzyme Block (Dako Omnis)	Put on appropriate personal protective equipment (see Section 8).
Anti-FITC-AP (Dako Omnis)	Put on appropriate personal protective equipment (see Section 8).
BCIP-NBT Substrate (Dako Omnis)	Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Avoid release to the environment. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

SECTION 7: Handling and storage

Advice on general occupational hygiene	:	CISH Endogenous Enzyme Block (Dako Omnis)	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
		Anti-FITC-AP (Dako Omnis)	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
		BCIP-NBT Substrate (Dako Omnis)	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Storage	:	CISH Endogenous Enzyme Block (Dako Omnis)	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.
		Anti-FITC-AP (Dako Omnis)	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.
		BCIP-NBT Substrate (Dako Omnis)	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations	:	CISH Endogenous Enzyme Block (Dako Omnis)	Industrial applications, Professional applications.
		Anti-FITC-AP (Dako Omnis)	Industrial applications, Professional applications.
		BCIP-NBT Substrate (Dako Omnis)	Industrial applications, Professional applications.

SECTION 7: Handling and storage

Industrial sector specific solutions	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not available.
		Anti-FITC-AP (Dako Omnis)	Not available.
		BCIP-NBT Substrate (Dako Omnis)	Not available.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
CISH Endogenous Enzyme Block (Dako Omnis)	
hydrogen peroxide solution	**NAOSH (Ireland, 5/2021). Notes: Advisory Occupational Exposure Limit Values (OELVs)** OELV-8hr: 1 ppm 8 hours. OELV-8hr: 1.5 mg/m³ 8 hours. OELV-15min: 2 ppm 15 minutes. OELV-15min: 3 mg/m³ 15 minutes.
BCIP-NBT Substrate (Dako Omnis)	
N, N-dimethylformamide	**NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU derived Occupational Exposure Limit Values** OELV-8hr: 5 ppm 8 hours. OELV-8hr: 15 mg/m³ 8 hours. OELV-15min: 10 ppm 15 minutes. OELV-15min: 30 mg/m³ 15 minutes.

Biological exposure indices

Product/ingredient name	Exposure indices
BCIP-NBT Substrate (Dako Omnis)	
N, N-dimethylformamide	**NAOSH (Ireland, 1/2011)** BMGV: 15 mg/l, N-methylformamide [in urine]. Sampling time: post shift.

Recommended monitoring procedures : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Product/ingredient name	Type	Exposure	Value	Population	Effects
CISH Endogenous Enzyme Block (Dako Omnis)					
hydrogen peroxide solution	DNEL	Long term Inhalation	0.21 mg/m³	General population	Local
	DNEL	Long term Inhalation	1.4 mg/m³	Workers	Local
	DNEL	Short term Inhalation	1.93 mg/m³	General population	Local
	DNEL	Short term Inhalation	3 mg/m³	Workers	Local
BCIP-NBT Substrate (Dako Omnis)					

SECTION 8: Exposure controls/personal protection

N, N-dimethylformamide	DNEL	Long term Inhalation	6 mg/m³	Workers	Systemic
	DNEL	Long term Dermal	1.1 mg/kg bw/day	Workers	Systemic
Magnesium chloride	DNEL	Long term Oral	7 mg/kg bw/day	General population	Systemic

PNECs

No PNECs available

8.2 Exposure controls

Appropriate engineering controls : If user operations generate dust, fumes, gas, vapour or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Body protection : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance

SECTION 9: Physical and chemical properties

Physical state	:	CISH Endogenous Enzyme Block (Dako Omnis)	Liquid.
		Anti-FITC-AP (Dako Omnis)	Liquid.
		BCIP-NBT Substrate (Dako Omnis)	Liquid.
Colour	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not available.
		Anti-FITC-AP (Dako Omnis)	Not available.
		BCIP-NBT Substrate (Dako Omnis)	Not available.
Odour	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not available.
		Anti-FITC-AP (Dako Omnis)	Not available.
		BCIP-NBT Substrate (Dako Omnis)	Not available.
Odour threshold	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not available.
		Anti-FITC-AP (Dako Omnis)	Not available.
		BCIP-NBT Substrate (Dako Omnis)	Not available.
Melting point/freezing point	:	CISH Endogenous Enzyme Block (Dako Omnis)	0°C
		Anti-FITC-AP (Dako Omnis)	Not available.
		BCIP-NBT Substrate (Dako Omnis)	0°C
Initial boiling point and boiling range	:	CISH Endogenous Enzyme Block (Dako Omnis)	100°C
		Anti-FITC-AP (Dako Omnis)	Not available.
		BCIP-NBT Substrate (Dako Omnis)	100°C
Flammability	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	Not applicable.
Upper/lower flammability or explosive limits	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not available.
		Anti-FITC-AP (Dako Omnis)	Not available.
		BCIP-NBT Substrate (Dako Omnis)	Not available.
Flash point	:		

SECTION 9: Physical and chemical properties

Ingredient name	Closed cup °C	Closed cup Method	Open cup °C	Open cup Method
BCIP-NBT Substrate (Dako Omnis)				
N, N-dimethylformamide	57.5	DIN 51755	-	-

Auto-ignition temperature :

Ingredient name	°C	Method
BCIP-NBT Substrate (Dako Omnis)		
N, N-dimethylformamide	445	-

Decomposition temperature :

CISH Endogenous Enzyme Block (Dako Omnis)	Not available.
Anti-FITC-AP (Dako Omnis)	Not available.
BCIP-NBT Substrate (Dako Omnis)	Not available.

pH :

CISH Endogenous Enzyme Block (Dako Omnis)	Not available.
Anti-FITC-AP (Dako Omnis)	7.5
BCIP-NBT Substrate (Dako Omnis)	9

Viscosity :

CISH Endogenous Enzyme Block (Dako Omnis)	Not available.
Anti-FITC-AP (Dako Omnis)	Not available.
BCIP-NBT Substrate (Dako Omnis)	Not available.

Solubility(ies) :

Media	Result
CISH Endogenous Enzyme Block (Dako Omnis)	
water	Soluble
Anti-FITC-AP (Dako Omnis)	
water	Soluble
BCIP-NBT Substrate (Dako Omnis)	
water	Soluble

Partition coefficient: n-octanol/water :

CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
Anti-FITC-AP (Dako Omnis)	Not applicable.
BCIP-NBT Substrate (Dako Omnis)	Not applicable.

Vapour pressure :

Ingredient name	Vapour Pressure at 20˚C mm Hg	Vapour Pressure at 20˚C kPa	Vapour Pressure at 20˚C Method	Vapour pressure at 50˚C mm Hg	Vapour pressure at 50˚C kPa	Vapour pressure at 50˚C Method
CISH Endogenous Enzyme Block (Dako Omnis)						
water	17.5	2.3	-	92.258	12.3	-
hydrogen peroxide solution	0.75	0.1	-	-	-	-

SECTION 9: Physical and chemical properties

Anti-FITC-AP (Dako Omnis)						
water	17.5	2.3	-	92.258	12.3	-
BCIP-NBT Substrate (Dako Omnis)						
water	17.5	2.3	-	92.258	12.3	-
N, N-dimethylformamide	3.7	0.49	-	-	-	-

Evaporation rate :
- CISH Endogenous Enzyme Block (Dako Omnis): Not available.
- Anti-FITC-AP (Dako Omnis): Not available.
- BCIP-NBT Substrate (Dako Omnis): Not available.

Relative density :
- CISH Endogenous Enzyme Block (Dako Omnis): Not available.
- Anti-FITC-AP (Dako Omnis): Not available.
- BCIP-NBT Substrate (Dako Omnis): Not available.

Vapour density :
- CISH Endogenous Enzyme Block (Dako Omnis): Not available.
- Anti-FITC-AP (Dako Omnis): Not available.
- BCIP-NBT Substrate (Dako Omnis): Not available.

Explosive properties :
- CISH Endogenous Enzyme Block (Dako Omnis): Not available.
- Anti-FITC-AP (Dako Omnis): Not available.
- BCIP-NBT Substrate (Dako Omnis): Not available.

Oxidising properties :
- CISH Endogenous Enzyme Block (Dako Omnis): Not available.
- Anti-FITC-AP (Dako Omnis): Not available.
- BCIP-NBT Substrate (Dako Omnis): Not available.

Particle characteristics

Median particle size :
- CISH Endogenous Enzyme Block (Dako Omnis): Not applicable.
- Anti-FITC-AP (Dako Omnis): Not applicable.
- BCIP-NBT Substrate (Dako Omnis): Not applicable.

9.2 Other information

No additional information.

SECTION 10: Stability and reactivity

10.1 Reactivity	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific test data related to reactivity available for this product or its ingredients.
		Anti-FITC-AP (Dako Omnis)	No specific test data related to reactivity available for this product or its ingredients.
		BCIP-NBT Substrate (Dako Omnis)	No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	:	CISH Endogenous Enzyme Block (Dako Omnis)	The product is stable.
		Anti-FITC-AP (Dako Omnis)	The product is stable.
		BCIP-NBT Substrate (Dako Omnis)	The product is stable.
10.3 Possibility of hazardous reactions	:	CISH Endogenous Enzyme Block (Dako Omnis)	Under normal conditions of storage and use, hazardous reactions will not occur.
		Anti-FITC-AP (Dako Omnis)	Under normal conditions of storage and use, hazardous reactions will not occur.
		BCIP-NBT Substrate (Dako Omnis)	Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	No specific data.
10.5 Incompatible materials	:	CISH Endogenous Enzyme Block (Dako Omnis)	May react or be incompatible with oxidising materials.
		Anti-FITC-AP (Dako Omnis)	May react or be incompatible with oxidising materials.
		BCIP-NBT Substrate (Dako Omnis)	May react or be incompatible with oxidising materials.
10.6 Hazardous decomposition products	:	CISH Endogenous Enzyme Block (Dako Omnis)	Under normal conditions of storage and use, hazardous decomposition products should not be produced.
		Anti-FITC-AP (Dako Omnis)	Under normal conditions of storage and use, hazardous decomposition products should not be produced.
		BCIP-NBT Substrate (Dako Omnis)	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

SECTION 11: Toxicological information

Product/ingredient name	Result	Species	Dose	Exposure
CISH Endogenous Enzyme Block (Dako Omnis)				
hydrogen peroxide solution	LD50 Dermal	Rabbit - Male, Female	>2000 mg/kg 35% solution	-
	LD50 Oral	Rat - Female	693.7 mg/kg 70% solution	-
Anti-FITC-AP (Dako Omnis)				
Polyoxyethylene octyl phenyl ether	LD50 Oral	Rat	1800 mg/kg	-
BCIP-NBT Substrate (Dako Omnis)				
N, N-dimethylformamide	LC50 Inhalation Vapour	Rat	3421 ppm	1 hours
	LC50 Inhalation Vapour	Rat	1948 ppm	4 hours
	LD50 Oral	Rat	4000 mg/kg	-
Magnesium chloride	LD50 Dermal	Rat - Male, Female	>2000 mg/kg	-
	LD50 Oral	Rat	2800 mg/kg	-

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
CISH Endogenous Enzyme Block (Dako Omnis)					
CISH Endogenous Enzyme Block (Dako Omnis)	12458.4	N/A	N/A	366.7	N/A
hydrogen peroxide solution	693.7	N/A	N/A	11	N/A
Anti-FITC-AP (Dako Omnis)					
Anti-FITC-AP (Dako Omnis)	27089.4	N/A	N/A	N/A	N/A
Polyoxyethylene octyl phenyl ether	1800	N/A	N/A	N/A	N/A
BCIP-NBT Substrate (Dako Omnis)					
BCIP-NBT Substrate (Dako Omnis)	N/A	88332.4	N/A	647.8	N/A
N, N-dimethylformamide	4000	1500	N/A	11	N/A
Magnesium chloride	2800	N/A	N/A	N/A	N/A

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
CISH Endogenous Enzyme Block (Dako Omnis)					
hydrogen peroxide solution	Eyes - Severe irritant	Rabbit	-	1 mg	-
Anti-FITC-AP (Dako Omnis)					
Polyoxyethylene octyl phenyl ether	Skin - Mild irritant	Rabbit	-	24 hours 500 uL	-
BCIP-NBT Substrate (Dako Omnis)					
N, N-dimethylformamide	Eyes - Severe irritant	Rabbit	-	100 %	-

Sensitiser

Conclusion/Summary : Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity

Conclusion/Summary : Not available.

SECTION 11: Toxicological information

Reproductive toxicity

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
CISH Endogenous Enzyme Block (Dako Omnis) hydrogen peroxide solution	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on likely routes of exposure

CISH Endogenous Enzyme Block (Dako Omnis)	Routes of entry anticipated: Oral, Dermal, Inhalation, Eyes.
Anti-FITC-AP (Dako Omnis)	Not available.
BCIP-NBT Substrate (Dako Omnis)	Routes of entry anticipated: Oral, Dermal, Inhalation, Eyes.

Potential acute health effects

Inhalation

CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.

Ingestion

CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.

Skin contact

CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.

Eye contact

CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

SECTION 11: Toxicological information

Inhalation	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations
Ingestion	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations
Skin contact	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations
Eye contact	:	CISH Endogenous Enzyme Block (Dako Omnis)	No specific data.
		Anti-FITC-AP (Dako Omnis)	No specific data.
		BCIP-NBT Substrate (Dako Omnis)	No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

Conclusion/Summary : Not available.

General	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.

SECTION 11: Toxicological information

Carcinogenicity	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.
Mutagenicity	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	No known significant effects or critical hazards.
Reproductive toxicity	:	CISH Endogenous Enzyme Block (Dako Omnis)	No known significant effects or critical hazards.
		Anti-FITC-AP (Dako Omnis)	No known significant effects or critical hazards.
		BCIP-NBT Substrate (Dako Omnis)	May damage the unborn child.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
CISH Endogenous Enzyme Block (Dako Omnis)			
hydrogen peroxide solution	Acute EC50 1.2 mg/l Marine water	Algae - *Dunaliella tertiolecta* - Exponential growth phase	72 hours
	Acute EC50 2320 µg/l Fresh water	Daphnia - *Daphnia magna* - Neonate	48 hours
	Acute LC50 93 ppm Fresh water	Fish - *Oncorhynchus mykiss*	96 hours
	Chronic NOEC 0.63 mg/l Fresh water	Daphnia - *Daphnia Magna*	21 days
	Chronic NOEC 100 mg/l Fresh water	Fish - *Micropterus salmoides*	28 days
Anti-FITC-AP (Dako Omnis)			
Polyoxyethylene octyl phenyl ether	Acute LC50 5.85 mg/l Fresh water	Crustaceans - *Ceriodaphnia rigaudi* - Neonate	48 hours
	Acute LC50 11.2 mg/l Fresh water	Daphnia - *Daphnia magna* - Neonate	48 hours
	Acute LC50 4500 µg/l Fresh water	Fish - *Pimephales promelas*	96 hours
	Chronic NOEC 0.004 mg/l Fresh water	Fish - *Gambusia holbrooki*	28 days
BCIP-NBT Substrate (Dako Omnis)			
N, N-dimethylformamide	Acute EC50 4500 mg/l Fresh water	Daphnia - *Daphnia magna*	48 hours
	Acute LC50 >100000 µg/l Marine water	Crustaceans - *Crangon crangon* - Adult	48 hours
	Acute LC50 7100000 µg/l Fresh water	Fish - *Lepomis macrochirus* - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Chronic NOEC 1500 mg/l Fresh water	Daphnia - *Daphnia magna*	21 days
	Chronic NOEC 0.1 ml/L Fresh water	Fish - *Oncorhynchus mykiss* - Embryo	30 days

SECTION 12: Ecological information

Magnesium chloride	Acute EC50 >100 mg/l Fresh water	Algae - *Desmodesmus subspicatus*	72 hours
	Acute EC50 180000 µg/l Fresh water	Crustaceans - *Eudiaptomus padanus ssp. padanus* - Adult	48 hours
	Acute IC50 6.8 mg/l Fresh water	Aquatic plants - *Lemna aequinoctialis*	96 hours
	Acute LC50 32000 µg/l Fresh water	Daphnia - *Daphnia hyalina* - Adult	48 hours
	Acute LC50 2120 mg/l Fresh water	Fish - *Pimephales promelas*	96 hours
	Acute NOEC 100 mg/l Fresh water	Algae - *Desmodesmus subspicatus*	72 hours
	Chronic NOEC 0.1 mg/l Fresh water	Fish - *Cyprinus carpio*	35 days

12.2 Persistence and degradability

Product/ingredient name	Test	Result	Dose	Inoculum
BCIP-NBT Substrate (Dako Omnis)				
N, N-dimethylformamide	-	100 % - Readily - 21 days	-	-

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
CISH Endogenous Enzyme Block (Dako Omnis)			
hydrogen peroxide solution	-	-	Readily
Anti-FITC-AP (Dako Omnis)			
Polyoxyethylene octyl phenyl ether	-	-	Readily
BCIP-NBT Substrate (Dako Omnis)			
N, N-dimethylformamide	-	-	Readily

12.3 Bioaccumulative potential

Product/ingredient name	$LogP_{ow}$	BCF	Potential
CISH Endogenous Enzyme Block (Dako Omnis)			
hydrogen peroxide solution	-1.36	-	Low
Anti-FITC-AP (Dako Omnis)			
Polyoxyethylene octyl phenyl ether	4.86	-	High
BCIP-NBT Substrate (Dako Omnis)			
N, N-dimethylformamide	-1.01	0.79	Low

12.4 Mobility in soil

Soil/water partition coefficient (K_{OC}) : Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

SECTION 12: Ecological information

12.6 Endocrine disrupting properties

Anti-FITC-AP (Dako Omnis) — Contains one or more substances considered to have endocrine-disrupting properties.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste : The classification of the product may meet the criteria for a hazardous waste.

Packaging

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Special precautions : Dispose of material(s) and residues under controlled conditions. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	IMDG	IATA
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-
14.3 Transport hazard class(es)	-	-	-
14.4 Packing group	-	-	-
14.5 Environmental hazards	No.	No.	No.

Additional information

14.6 Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments : Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

Ingredient name	Intrinsic property	Status	Reference number	Date of revision
Anti-FITC-AP (Dako Omnis) Polyoxyethylene octyl phenyl ether	Endocrine disrupting properties for environment	Listed	42	7/3/2017

Substances of very high concern

Ingredient name	Intrinsic property	Status	Reference number	Date of revision
Anti-FITC-AP (Dako Omnis) Polyoxyethylene octyl phenyl ether	Endocrine disrupting properties for environment	Recommended	ED/169/2012	7/3/2017
BCIP-NBT Substrate (Dako Omnis) N,N-Dimethylformamide	Toxic to reproduction	Recommended	ED/169/2012	2/6/2014

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product / Ingredient name	Identifiers	Designation [Usage]
BCIP-NBT Substrate (Dako Omnis) BCIP-NBT Substrate (Dako Omnis)	-	3 30
N, N-dimethylformamide	EC: 200-679-5 CAS: 68-12-2 Index: 616-001-00-X	30 76

Label	:	CISH Endogenous Enzyme Block (Dako Omnis)	Not applicable.
		Anti-FITC-AP (Dako Omnis)	Not applicable.
		BCIP-NBT Substrate (Dako Omnis)	Restricted to professional users.

Other EU regulations

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Persistent Organic Pollutants

Not listed.

Seveso Directive

This product is not controlled under the Seveso Directive.

National regulations

Product/ingredient name	List name	Name on list	Classification	Notes
BCIP-NBT Substrate (Dako Omnis) N, N-dimethylformamide	Ireland Occupational Exposure Limits	dimethylformamide	Repro. Repr.1B	-

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

SECTION 15: Regulatory information

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia	:	Not determined.
Canada	:	Not determined.
China	:	Not determined.
Eurasian Economic Union	:	**Russian Federation inventory**: Not determined.
Japan	:	**Japan inventory (CSCL)**: Not determined. **Japan inventory (ISHL)**: Not determined.
New Zealand	:	Not determined.
Philippines	:	Not determined.
Republic of Korea	:	Not determined.
Taiwan	:	All components are listed or exempted.
Thailand	:	Not determined.
Turkey	:	Not determined.
United States	:	All components are active or exempted.
Viet Nam	:	Not determined.

15.2 Chemical safety assessment : This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms :
ATE = Acute Toxicity Estimate
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
N/A = Not available
PBT = Persistent, Bioaccumulative and Toxic
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number
vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
BCIP-NBT Substrate (Dako Omnis)	
Repr. 1B, H360D	Calculation method
Aquatic Chronic 3, H412	Calculation method

Full text of abbreviated H statements

SECTION 16: Other information

CISH Endogenous Enzyme Block (Dako Omnis)	
H271	May cause fire or explosion; strong oxidiser.
H302	Harmful if swallowed.
H314	Causes severe skin burns and eye damage.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
Anti-FITC-AP (Dako Omnis)	
H302	Harmful if swallowed.
H315	Causes skin irritation.
H318	Causes serious eye damage.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
BCIP-NBT Substrate (Dako Omnis)	
H312	Harmful in contact with skin.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H360D	May damage the unborn child.
H410	Very toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.

Full text of classifications [CLP/GHS]

CISH Endogenous Enzyme Block (Dako Omnis)	
Acute Tox. 4	ACUTE TOXICITY - Category 4
Ox. Liq. 1	OXIDISING LIQUIDS - Category 1
Skin Corr. 1A	SKIN CORROSION/IRRITATION - Category 1A
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3
Anti-FITC-AP (Dako Omnis)	
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
BCIP-NBT Substrate (Dako Omnis)	
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Repr. 1B	REPRODUCTIVE TOXICITY - Category 1B

Date of issue/ Date of revision : 12/11/2024

Date of previous issue : 20/10/2023

Version : 3

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.